An open-label extension study to evaluate the efficacy and safety of Roxadustat for the long-term maintenance treatment of anemia in dialysis and non-dialysis patients with CKD
Category: Anemia and Iron Metabolism: Clinical
Authors: Chao H. Sun MD, FASN; Elizabeth A. Barranco MD; Lona Poole, MD; Meraf Eyassu RN; Cameron S. Liu PhD; Donna L. Kline; Thomas B. Neff; Kin-Hung Peony Yu, MD
Roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, stimulates erythropoiesis by increasing erythropoietin, and regulates iron metabolism.
An open-label, extension study originally included 14 subjects with non-dialysis-dependent chronic kidney disease (NDD-CKD) and 1 subject with dialysis-dependent chronic kidney disease (DD-CKD). After enrollment, 2 of the subjects ended up being excluded from analyses – one with NDD-CKA withdrew consent two weeks post-enrollment and one with DD-CKD was excluded.